ATE454472T1 - C1ckb-mutation als diagnostisches und therapeutisches ziel - Google Patents

C1ckb-mutation als diagnostisches und therapeutisches ziel

Info

Publication number
ATE454472T1
ATE454472T1 AT04765865T AT04765865T ATE454472T1 AT E454472 T1 ATE454472 T1 AT E454472T1 AT 04765865 T AT04765865 T AT 04765865T AT 04765865 T AT04765865 T AT 04765865T AT E454472 T1 ATE454472 T1 AT E454472T1
Authority
AT
Austria
Prior art keywords
nucleic acid
acid molecule
clckb
allergy
infection
Prior art date
Application number
AT04765865T
Other languages
English (en)
Inventor
Florian Lang
Siegfried Waldegger
Philipp Lang
Angelika Lampert
Hannsjoerg Seybert
Dr Nikola Jeck
Original Assignee
Univ Eberhard Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Eberhard Karls filed Critical Univ Eberhard Karls
Application granted granted Critical
Publication of ATE454472T1 publication Critical patent/ATE454472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
AT04765865T 2003-10-15 2004-10-07 C1ckb-mutation als diagnostisches und therapeutisches ziel ATE454472T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/687,523 US7074573B2 (en) 2003-10-15 2003-10-15 CLCKb mutation as a diagnostic therapeutical target
PCT/EP2004/011192 WO2005040417A1 (en) 2003-10-15 2004-10-07 C1CKb MUTATION AS A DIAGNOSTIC AND THERAPEUTICAL TARGET

Publications (1)

Publication Number Publication Date
ATE454472T1 true ATE454472T1 (de) 2010-01-15

Family

ID=34520994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765865T ATE454472T1 (de) 2003-10-15 2004-10-07 C1ckb-mutation als diagnostisches und therapeutisches ziel

Country Status (5)

Country Link
US (2) US7074573B2 (de)
EP (1) EP1673474B1 (de)
AT (1) ATE454472T1 (de)
DE (1) DE602004025017D1 (de)
WO (1) WO2005040417A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304768B1 (it) * 1998-10-05 2001-03-29 Esaote Spa Lettino porta paziente o simili, e macchina, in particolare macchinaper il rilevamento d'immagini in risonanza magnetica nucleare in
DE102005025799A1 (de) * 2005-06-02 2006-12-21 Eberhard-Karls-Universität Tübingen Verfahren zur Diagnose eines gestörten Magnesiumkanals
WO2011082382A2 (en) * 2009-12-31 2011-07-07 The Trustees Of Columbia University In The City Of New York Methods for detecting and regulating alopecia areata and gene cohorts thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9679998A (en) 1997-10-01 1999-04-23 Yale University Methods to modulate blood pressure and diagnose bartter's syndrome type iii
US20040234967A1 (en) 2000-03-24 2004-11-25 Moskowitz David W. Diagnostic polymorphisms of tgf-beta-rii promoter

Also Published As

Publication number Publication date
DE602004025017D1 (de) 2010-02-25
EP1673474B1 (de) 2010-01-06
WO2005040417A1 (en) 2005-05-06
US7235364B2 (en) 2007-06-26
US20050084485A1 (en) 2005-04-21
US7074573B2 (en) 2006-07-11
US20060240459A1 (en) 2006-10-26
EP1673474A1 (de) 2006-06-28

Similar Documents

Publication Publication Date Title
Sottrup-Jensen et al. Primary structure of human alpha 2-macroglobulin. V. The complete structure.
PL2157192T3 (pl) Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
ATE365213T1 (de) Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
ATE364698T1 (de) Neues, physiologisch aktives peptid und dessen verwendung
BRPI0413076B8 (pt) processo analítico para composições de pancreatina e comparáveis
DE602004009705D1 (de) Methoden der Verhinderung und Behandlung der Alzheimer'schen Krankheit
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
BRPI0409924A (pt) ácidos amino carboxìlicos substituìdos
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
RU2432360C2 (ru) Вариант еро, обладающий повышенным сродством связывания с рецептором и сниженным антигенным потенциалом, днк, кодирующая такой вариант еро, рекомбинантный экспрессионный вектор, содержащий такую днк, клетка-хозяин, трансформированная или трансфектированная таким вектором, способ получения такого варианта еро и фармацевтическая композиция, содержащая такой вариант еро
WO2003093316A3 (en) Immunoglobulin-domain containing cell surface recognition molecules
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
BR0215284A (pt) Polipeptìdeo, fragmento ou equivalente funcional, molécula de ácido nucléico purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptìdeo, composição farmacêutica, composição de vacina, método para tratar uma doença em um paciente, método para monitorar o tratamento terapêutico de doença em um paciente, método para a identificação de um composto, kit, animal não humano transgênico ou de inativação, e, método para triar um composto efetivo para tratar doença
DE602004025017D1 (de) C1ckb-mutation als diagnostisches und therapeutisches ziel
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
BRPI0409802A (pt) método para identificar um membro da famìlia secfam3, polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polìpeptìdeo, composição farmacêutica, composição de vacina, métodos para tratar uma doença em um paciente, para monitorar o tratamento terapêutico de doença em um paciente, e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou silenciado, e, método para triar para um composto eficaz para tratar doença
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
HK1092185A (en) Clckb mutation as a diagnostic and therapeutical target
EA200300642A1 (ru) Связанные с шизофренией ген и белок потенциал-зависимого воротного ионного канала
Shibata et al. Disruption of structural and functional integrity of α2‐macroglobulin by cathepsin E
BRPI0408510A (pt) métodos de identificar um membro da famìlia secfam1, de diagnosticar e de tratar uma doença em um paciente, de monitorar o tratamento terapêutico de doença em um paciente, de identificar um composto, e de triar quanto a um composto eficaz para tratar doença, polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, ligando, composto, uso de um polipeptìdeo, composição farmacêutica, composição de vacima, kit, e, animal não humano transgênico ou de abatimento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties